Genetic Technologies Limited (NASDAQ:GENE) Q3 2022 Earnings Conference Call April 20, 2022 6:00 PM ET Company Participants Simon Morriss – Chief Executive Officer Mike Tonroe – Chief Financial Officer Dr. George Muchnik – Non-Executive Director and Medical Advisor Conference Call Participants MichaelTonroe Hello and welcome to our Quarter Three business update. I'm Mike Tonroe, Chief Financial Officer Genetic Technologies. I'm also your house and moderator. Thank you for taking the time to join us today. Th ...

Exhibit 99.41 HALF YEAR REPORT Genetic Technologies Limited Appendix 4D Half-year ended 31 December 2021 Name of entity: Genetic Technologies Limited ABN: 17 009 212 328 Half-year ended: 31 December 2021 Previous period: 31 December 2020 Results for announcement to the market | | | | | $ | | --- | --- | --- | --- | --- | | Revenue for ordinary activities | Up | 12,379% | to | 2,051,016 | | Net loss after tax (from ordinary activities) for the period | | | | | | attributable to members | Up | (11.7)% | to | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR (Address of principal executive offices) Simon Morriss, Chief Executive O ...

Genetic Technologies Limited (NASDAQ:GENE) Quarterly Investor Webinar January 27, 2021 7:30 PM ET Company Participants Stephanie Ottens - Investor Relations George Muchnicki - Acting Chief Executive Officer Peter Rubinstein - Chairman Richard Allman - Chief Scientific Officer Conference Call Participants Stephanie Ottens Good morning and welcome everyone to Genetic Technologies Quarterly Investor Webinar. And we have the pleasure this morning to have from Genetic, Dr. George Muchnicki, Acting CEO on the res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F [ ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR [ ] SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...